Compare LASE & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LASE | NSRX |
|---|---|---|
| Founded | 2019 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.7M | 63.4M |
| IPO Year | 2022 | 2025 |
| Metric | LASE | NSRX |
|---|---|---|
| Price | $2.73 | $6.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | ★ 268.4K | 2.8K |
| Earning Date | 04-02-2026 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,938,027.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 89.34 | N/A |
| 52 Week Low | $1.71 | $5.90 |
| 52 Week High | $7.31 | $9.99 |
| Indicator | LASE | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | N/A |
| Support Level | $2.70 | N/A |
| Resistance Level | $3.06 | N/A |
| Average True Range (ATR) | 0.22 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 4.92 | 0.00 |
Laser Photonics Corp is an integrated manufacturing company for photonics-based industrial products and solutions, laser cleaning technologies. Its laser-blasting technologies are focused on disrupting the sandblasting and abrasives blasting markets. The company offers a portfolio of integrated laser-blasting solutions for corrosion control, rust removal, de-coating, pre-welding and post-welding, laser cleaning, and surface conditioning. Its laser-blasting solutions are applicable in every industry dealing with materials processing, including automotive, aerospace, healthcare, consumer products, shipbuilding, aerospace, machine manufacturing, nuclear maintenance and de-commissioning, and surface coating.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.